CN105709019A - Medicine for treating lung cancer and metastatic diseases thereof - Google Patents
Medicine for treating lung cancer and metastatic diseases thereof Download PDFInfo
- Publication number
- CN105709019A CN105709019A CN201410835214.0A CN201410835214A CN105709019A CN 105709019 A CN105709019 A CN 105709019A CN 201410835214 A CN201410835214 A CN 201410835214A CN 105709019 A CN105709019 A CN 105709019A
- Authority
- CN
- China
- Prior art keywords
- grams
- gram
- radix
- medicine
- pulmonary carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine for treating lung cancer and metastatic diseases thereof. The medicine consists of the following components: 5-10g of radix scutellariae, 5-10g of radix angelicae, 5-10g of semen ginkgo, 5-10g of manyleaf paris rhizome, 2-5g of scorpion, 15-25g of herba lobeliae chinensis, 5-10g of rhizoma belamcandae, 5-10g of hemsleya amabilis diels, 5-10g of radix semiaquilegiae, 5-10g of herba andrographis, 5-10g of radix gynurae, 5-10g of roots of corniculate cayratia, 5-10g of rhizoma dioscoreae bulbiferae, 5-10g of radix stephaniae cepharanthae, 15-25g of herba houttuyniae, 5-10g of rhizoma corydalis decumbentis, 1-3g of cordyceps sinensis and 10g of liquorice roots. The medicine disclosed by the invention can enhance immunity, avoid the generation of side effects, reduce cost and price, and meet the demands of patients.
Description
Technical field
The present invention relates to a kind of medicine, particularly relate to a kind of medicine treating pulmonary carcinoma and transitivity disease thereof.
Background technology
Pulmonary carcinoma is that M & M increases the soonest, one of malignant tumor maximum to population health and life threat.The many countries of immediate and mid-term all report that the M & M of pulmonary carcinoma all substantially increases, and male lung cancer M & M all accounts for first of all malignant tumor, and women sickness rate accounts for second, and mortality rate accounts for second.So far still not exclusively clearly, great mass of data shows the cause of disease of pulmonary carcinoma, and long-term a large amount of smokings have very close relationship with pulmonary carcinoma.Existing research proves: the probability that long-term a large amount of smokers suffer from pulmonary carcinoma is 10～20 times of non-smoker, and the age starting smoking is more little, and the probability suffering from pulmonary carcinoma is more high.Additionally, smoking not only directly affects my healthy, also the health of surrounding population is produced harmful effect, cause that involuntary smoker's pulmonary carcinoma prevalence substantially increases.The sickness rate of urbanite's pulmonary carcinoma is higher than rural area, and this is likely to relevant containing carcinogen with urban atmospheric pollution and flue dust.The transitivity disease of pulmonary carcinoma refers to that the malignant tumor at any position is transferred to the tumor of pulmonary by various branch modes, just has neoplasm metastasis when the malignant tumor of about more than 60% is medical for the first time, and wherein 30%～50% neoplasm metastasis is to pulmonary.Chemotherapy is the therapeutic modality of a kind of pulmonary carcinoma, but chemotherapy can be with to patient and serve side effect, as alopecia, feel sick, immunity degradation, leukocyte reduction etc..
Summary of the invention
The technical problem to be solved is to provide a kind of medicine treating pulmonary carcinoma and transitivity disease thereof, and it improves immunity, will not have side effects.
The present invention solves above-mentioned technical problem by following technical proposals: a kind of medicine treating pulmonary carcinoma and transitivity disease thereof, it is characterized in that, it is composed of the following components: Radix Scutellariae 5-10 gram, Radix Angelicae Dahuricae 5-10 gram, Semen Ginkgo 5-10 gram, Rhizoma Paridis 5-10 gram, Scorpio 2-5 gram, Herba Lobeliae Chinensis 15-25 gram, Rhizoma Belamcandae 5-10 gram, Radix Hemsleyae Macrospermae 5-10 gram, Radix Semiaquilegiae 5-10 gram, Herba Andrographitis 5-10 gram, Radix gynurae segeti 5-10 gram, nine Fructus Arctii 5-10 gram, Rhizoma Dioscoreae Bulbiferae 5-10 gram, Radix Stephaniae Cepharanthae 5-10 gram, Herba Houttuyniae 15-25 gram, Rhizoma Corydalis Decumbentis 5-10 gram, Cordyceps 1-3 gram, 10 grams of Radix Glycyrrhizae.
Preferably, described Radix Scutellariae is 7 grams.
Preferably, the described Radix Angelicae Dahuricae is 7 grams.
Preferably, described Semen Ginkgo is 7 grams.
Preferably, described Rhizoma Paridis is 7 grams.
Preferably, described Scorpio is 3 grams.
Preferably, described Herba Lobeliae Chinensis is 20 grams.
Preferably, described Rhizoma Belamcandae is 7 grams.
Preferably, described Radix Hemsleyae Macrospermae is 7 grams.
Preferably, described Radix Semiaquilegiae is 7 grams.
The actively progressive effect of the present invention is in that: the present invention improves immunity, will not have side effects, and reduces cost and price, meets sick human needs.
Detailed description of the invention
The medicine that the present invention treats pulmonary carcinoma and transitivity disease thereof is composed of the following components: Radix Scutellariae 5-10 gram, Radix Angelicae Dahuricae 5-10 gram, Semen Ginkgo 5-10 gram, Rhizoma Paridis 5-10 gram, Scorpio 2-5 gram, Herba Lobeliae Chinensis 15-25 gram, Rhizoma Belamcandae 5-10 gram, Radix Hemsleyae Macrospermae 5-10 gram, Radix Semiaquilegiae 5-10 gram, Herba Andrographitis 5-10 gram, Radix gynurae segeti 5-10 gram, nine Fructus Arctii 5-10 gram, Rhizoma Dioscoreae Bulbiferae 5-10 gram, Radix Stephaniae Cepharanthae 5-10 gram, Herba Houttuyniae 15-25 gram, Rhizoma Corydalis Decumbentis 5-10 gram, Cordyceps 1-3 gram, 10 grams of Radix Glycyrrhizae.Radix Scutellariae preferably 7 grams.The Radix Angelicae Dahuricae preferably 7 grams.Semen Ginkgo preferably 7 grams.Rhizoma Paridis preferably 7 grams.Scorpio preferably 3 grams.Herba Lobeliae Chinensis preferably 20 grams.Rhizoma Belamcandae preferably 7 grams.Radix Hemsleyae Macrospermae preferably 7 grams.Radix Semiaquilegiae preferably 7 grams.Herba Andrographitis preferably 7 grams.Radix gynurae segeti preferably 7 grams.Nine Fructus Arctii preferably 7 grams.Rhizoma Dioscoreae Bulbiferae preferably 7 grams.Radix Stephaniae Cepharanthae preferably 7 grams.Herba Houttuyniae preferably 20 grams.Rhizoma Corydalis Decumbentis preferably 7 grams.Cordyceps preferably 2 grams.
Typical case is as follows:
1, Zhang, man, 32 years old, after taking two week of medicine that the present invention treats pulmonary carcinoma and transitivity disease thereof, immunity strengthened.Use the following components of the present invention: Radix Scutellariae 5 grams, the Radix Angelicae Dahuricae 5 grams, Semen Ginkgo 5 grams, Rhizoma Paridis 5 grams, Scorpio 2 grams, Herba Lobeliae Chinensis 15 grams, Rhizoma Belamcandae 5 grams, Radix Hemsleyae Macrospermae 5 grams, Radix Semiaquilegiae 5 grams, Herba Andrographitis 5 grams, Radix gynurae segeti 5 grams, nine Fructus Arctii 5 grams, Rhizoma Dioscoreae Bulbiferae 5 grams, Radix Stephaniae Cepharanthae 5 grams, Herba Houttuyniae 15 grams, Rhizoma Corydalis Decumbentis 5 grams, Cordyceps 1 gram, 10 grams of Radix Glycyrrhizae.
2, Korea Spro so-and-so, female, 31 years old, take the present invention and treat the medicine of pulmonary carcinoma and transitivity disease thereof after two months, immunity strengthen, sb.'s illness took a favorable turn.Use the following components of the present invention: Radix Scutellariae 10 grams, the Radix Angelicae Dahuricae 10 grams, Semen Ginkgo 10 grams, Rhizoma Paridis 10 grams, Scorpio 5 grams, Herba Lobeliae Chinensis 25 grams, Rhizoma Belamcandae 10 grams, Radix Hemsleyae Macrospermae 10 grams, Radix Semiaquilegiae 10 grams, Herba Andrographitis 10 grams, Radix gynurae segeti 10 grams, nine Fructus Arctii 10 grams, Rhizoma Dioscoreae Bulbiferae 10 grams, Radix Stephaniae Cepharanthae 10 grams, Herba Houttuyniae 25 grams, Rhizoma Corydalis Decumbentis 10 grams, Cordyceps 3 grams, 10 grams of Radix Glycyrrhizae.,
3, Chen, man, 33 years old, to take the present invention and treat the medicine of pulmonary carcinoma and transitivity disease thereof after one month, immunity strengthens, and sb.'s illness took a favorable turn.Use the following components of the present invention: Radix Scutellariae 7 grams, the Radix Angelicae Dahuricae 7 grams, Semen Ginkgo 7 grams, Rhizoma Paridis 7 grams, Scorpio 3 grams, Herba Lobeliae Chinensis 20 grams, Rhizoma Belamcandae 7 grams, Radix Hemsleyae Macrospermae 7 grams, Radix Semiaquilegiae 7 grams, Herba Andrographitis 7 grams, Radix gynurae segeti 7 grams, nine Fructus Arctii 7 grams, Rhizoma Dioscoreae Bulbiferae 7 grams, Radix Stephaniae Cepharanthae 7 grams, Herba Houttuyniae 20 grams, Rhizoma Corydalis Decumbentis 7 grams, Cordyceps 2 grams, 10 grams of Radix Glycyrrhizae.
What the present invention adopted is all Chinese medicinal herbs, improves immunity, will not have side effects, and reduces cost and price, meets sick human needs.The present invention breaks into fine powder and brews one hour with boiled water, and filter and remove residue stays water to take, and conveniently drinks.
The present invention can be carried out various remodeling and change by those skilled in the art.Therefore, present invention covers the various remodeling in the scope falling into appending claims and equivalent thereof and change.
Claims (10)
1. the medicine treating pulmonary carcinoma and transitivity disease thereof, it is characterized in that, it is composed of the following components: Radix Scutellariae 5-10 gram, Radix Angelicae Dahuricae 5-10 gram, Semen Ginkgo 5-10 gram, Rhizoma Paridis 5-10 gram, Scorpio 2-5 gram, Herba Lobeliae Chinensis 15-25 gram, Rhizoma Belamcandae 5-10 gram, Radix Hemsleyae Macrospermae 5-10 gram, Radix Semiaquilegiae 5-10 gram, Herba Andrographitis 5-10 gram, Radix gynurae segeti 5-10 gram, nine Fructus Arctii 5-10 gram, Rhizoma Dioscoreae Bulbiferae 5-10 gram, Radix Stephaniae Cepharanthae 5-10 gram, Herba Houttuyniae 15-25 gram, Rhizoma Corydalis Decumbentis 5-10 gram, Cordyceps 1-3 gram, 10 grams of Radix Glycyrrhizae.
2. the medicine for the treatment of pulmonary carcinoma as claimed in claim 1 and transitivity disease thereof, it is characterised in that described Radix Scutellariae is 7 grams.
3. the medicine for the treatment of pulmonary carcinoma as claimed in claim 1 and transitivity disease thereof, it is characterised in that the described Radix Angelicae Dahuricae is 7 grams.
4. the medicine for the treatment of pulmonary carcinoma as claimed in claim 1 and transitivity disease thereof, it is characterised in that described Semen Ginkgo is 7 grams.
5. the medicine for the treatment of pulmonary carcinoma as claimed in claim 1 and transitivity disease thereof, it is characterised in that described Rhizoma Paridis is 7 grams.
6. the medicine for the treatment of pulmonary carcinoma as claimed in claim 1 and transitivity disease thereof, it is characterised in that described Scorpio is 3 grams.
7. the medicine for the treatment of pulmonary carcinoma as claimed in claim 1 and transitivity disease thereof, it is characterised in that described Herba Lobeliae Chinensis is 20 grams.
8. the medicine for the treatment of pulmonary carcinoma as claimed in claim 1 and transitivity disease thereof, it is characterised in that described Rhizoma Belamcandae is 7 grams.
9. the medicine for the treatment of pulmonary carcinoma as claimed in claim 1 and transitivity disease thereof, it is characterised in that described Radix Hemsleyae Macrospermae is 7 grams.
10. the medicine for the treatment of pulmonary carcinoma as claimed in claim 1 and transitivity disease thereof, it is characterised in that described Radix Semiaquilegiae is 7 grams.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410835214.0A CN105709019A (en) | 2014-12-25 | 2014-12-25 | Medicine for treating lung cancer and metastatic diseases thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410835214.0A CN105709019A (en) | 2014-12-25 | 2014-12-25 | Medicine for treating lung cancer and metastatic diseases thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105709019A true CN105709019A (en) | 2016-06-29 |
Family
ID=56144644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410835214.0A Pending CN105709019A (en) | 2014-12-25 | 2014-12-25 | Medicine for treating lung cancer and metastatic diseases thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105709019A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1110569A (en) * | 1994-04-23 | 1995-10-25 | 蒋立范 | Traditional Chinese medicine for treating lung cancer and its preparation method |
| CN1377701A (en) * | 2002-04-24 | 2002-11-06 | 仇淑兰 | Traditional Chinese medicine preparation for curing cancer and preparing process |
| CN1509758A (en) * | 2002-12-23 | 2004-07-07 | 江苏康缘药业股份有限公司 | Chinese medicinal composition for treating lung cancer, preparing method and quality controlling method thereof |
| CN101081291A (en) * | 2007-04-25 | 2007-12-05 | 赵清鹏 | Medicine for treating cancer |
-
2014
- 2014-12-25 CN CN201410835214.0A patent/CN105709019A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1110569A (en) * | 1994-04-23 | 1995-10-25 | 蒋立范 | Traditional Chinese medicine for treating lung cancer and its preparation method |
| CN1377701A (en) * | 2002-04-24 | 2002-11-06 | 仇淑兰 | Traditional Chinese medicine preparation for curing cancer and preparing process |
| CN1509758A (en) * | 2002-12-23 | 2004-07-07 | 江苏康缘药业股份有限公司 | Chinese medicinal composition for treating lung cancer, preparing method and quality controlling method thereof |
| CN101081291A (en) * | 2007-04-25 | 2007-12-05 | 赵清鹏 | Medicine for treating cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104082465A (en) | Tea for regulating ovarian cancer | |
| CN104173848A (en) | Tea capable of conditioning lung cancer | |
| CN104491740A (en) | Traditional Chinese medicine composition for treating liver cancer and preparation method of traditional Chinese medicine composition | |
| CN105558120A (en) | Health tea formula | |
| CN102114230B (en) | Medicament for treating psoriasis | |
| CN103830696A (en) | Traditional Chinese medicine for treating pulmonary emphysema | |
| CN105709019A (en) | Medicine for treating lung cancer and metastatic diseases thereof | |
| CN105233017A (en) | Traditional Chinese medicine decoction for treatment of lung-deficiency cough | |
| CN104095112A (en) | Tea capable of alleviating laryngeal cancer | |
| CN103071112B (en) | Traditional Chinese medicine for curing nasopharynx cancer | |
| CN105641419A (en) | Traditional Chinese medicine composition for treating Yin deficiency type cough caused by lung cancer | |
| CN100393346C (en) | Traditional Chinese medicine for treating leuhemia | |
| CN103800812A (en) | Traditional Chinese medicine radix curcumae-tangerine peel powder for treating anorexia | |
| CN103285336B (en) | Chinese medicinal preparation for treating aplastic anemia | |
| CN105687450A (en) | Medicament capable of treating lung cancer by virtue of combined treatment of traditional Chinese medicine and western medicine | |
| CN1136896C (en) | Live-nourishing 'yanggan' pill | |
| CN105708939A (en) | Medicine for treating gastrointestinal cancer and metastatic diseases thereof | |
| CN104940689A (en) | Traditional Chinese medicine for treating lung cancer | |
| CN105709061A (en) | Medicine for treating cancer | |
| CN104873816A (en) | Lung-moistening traditional Chinese medicine | |
| CN104056186A (en) | Traditional Chinese medicine formula for treating esophagus cancer | |
| CN105641395A (en) | Traditional Chinese medicinal prescription for treating chronic pharyngitis | |
| CN103110808B (en) | A kind of Chinese drugs agentia for mitigating cancer of the esophagus radiotheraphy secondary reaction | |
| CN104998115B (en) | A kind of Chinese medicine composition and preparation method thereof for treating chronic pharyngitis | |
| CN104524369A (en) | Medicinal liquor for treatment of hemorrhoids and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160629 |
|
| WD01 | Invention patent application deemed withdrawn after publication |